AsiaTIDES: Oligonucleotide and Peptide® Research, Technology and Product Development
Clinical Development of Mipomersen, an Antisense Second-Generation Oligonucleotide Targeting Apolipoprotein B
Tejdip Singh, M.D., Medical Director, Global Patient Safety and Risk Management, Genzyme Corporation, USA
Oligonucleotide and Delivery Platform Optimization Strategies for siRNA Drug Development
Laura Sepp-Lorenzino, Ph.D., Senior Director, RNA Therapeutics, Merck & Co., Inc., USA
Recent Advances in Routes of Delivery for Peptide Pharmaceuticals
Nozer Mehta, Ph.D., Vice President, R&D, UniGene Laboratories, Inc., USA
Overview of Peptide Therapeutics and Vaccines in Development
Yuji Heike, M.D., Ph.D., Chief of Medical Staff, Department of Medical Oncology, National Cancer Center Hospital, Japan
Evolution and Development of GLP-1 Based Therapeutics
Andrew A. Young, M.D., Ph.D., Vice President, Head, Enterendocrine Biology, GlaxoSmithKline, USA
A Pivotal Year for Oligonucleotide Therapeutics
Arthur A. Levin, Ph.D., Chief Development Officer, Santaris A/S, USA and Denmark
RaPID Selection of a New Class of Peptide Drug Leads against Various Therapeutic Targets
Hiroaki Suga, Ph.D., Professor, Chemical Biology and Biotechnology Lab, The University of Tokyo, Japan
醫藥品業界無疑會繼續對胜肽（ Peptide）及寡核酸（Oligonucleotide）藥劑開發進行龐大金額的投資。
AsiaTIDES是能獲得以寡核酸及胜肽（ Peptide）作為基礎之治療藥的最新研究動向及有關製造技術的最新動向，是進入迅速發展市場的唯一機會。請聆聽全世界的最新報告。在東京舉行、非常方便的論壇，具有日本其他活動沒有的計畫內容。
『第一次參加AsiaTIDES，非常有意義。AsiaTIDES提供給我的公司多方面且有意義的資訊。能與來自歐美和亞洲企業的參加者交流，實感無上光榮。針對寡核酸設定了非常平衡的主題。很高興能參加此會議。』 - 日油株式會社 首席研究員 秋山義次博士
為充實投資組合和管道，遇見新的顧客，發現未來的合夥人，能獲得確保這些治療藥市場穩定市佔率的傳遞技術之最新動向。
中文官方網站營運：IBC Life Sciences 代理商 日商環球訊息有限公司